1 – 10 of 12
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study : high white blood cell count at diagnosis is the strongest prognostic factor
(
- Contribution to journal › Article
- 2018
-
Mark
Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010) : a prospective, intergroup, open-label, single-arm clinical trial
(
- Contribution to journal › Article
-
Mark
Predictive value of minimal residual disease in philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
(
- Contribution to journal › Article
-
Mark
Long-term survivors of childhood cancer : cure and care—the Erice Statement (2006) revised after 10 years (2016)
(
- Contribution to journal › Article
- 2016
-
Mark
The SIOPE strategic plan : A European cancer plan for children and adolescents
(
- Contribution to journal › Article
-
Mark
The european hematology association roadmap for european hematology research : A consensus document
(
- Contribution to journal › Article
- 2014
-
Mark
Comparison of MRD monitoring by IG/TR rearrangement and BCR/ABL1 transcript in PH+ pediatric acute lymphoblastic leukemia patients treated with imatinib in the EsPhALL study
(
- Contribution to journal › Published meeting abstract
- 2012
-
Mark
Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study
(
- Contribution to journal › Article
-
Mark
An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia
(
- Contribution to journal › Article
- 2011
-
Mark
Efficacy and safety of imatinib on top of BFM-like chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL). the EsPhALL study
(
- Contribution to journal › Published meeting abstract